<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68942">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02208310</url>
  </required_header>
  <id_info>
    <org_study_id>CCFA-329225</org_study_id>
    <nct_id>NCT02208310</nct_id>
  </id_info>
  <brief_title>Trial of High Dose Vitamin D in Patient's With Crohn's Disease</brief_title>
  <acronym>RODIN-CD</acronym>
  <official_title>A Randomized Controlled Trial of High-Dose Vitamin D in Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crohn's and Colitis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crohn's disease is more common in areas of the world with less sunlight exposure. Sunlight
      is a major source of vitamin D. There is some research to suggest that patient's with higher
      vitamin D levels are less likely to undergo surgeries and have better control of their
      disease. We intend to study the effects of high dose vitamin D supplementation in patients
      with vitamin D deficiency and Crohn's disease. We hypothesize that patients given high doses
      will have less hospitalizations, surgeries, steroid use.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to enroll at the rate anticipated, insufficient low vitamin D in clinical remission at
    5 sites
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Composite Outcome</measure>
    <time_frame>1 year</time_frame>
    <description>Crohn's disease(CD)-related hospitalizations, CD-related surgeries, CD-related ER visits, steroid prescriptions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypercalcemia</measure>
    <time_frame>1 year</time_frame>
    <description>Calcium &gt;10.8 mg/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of nephrolithiasis</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of nephrolithiasis associated with hypercalcemia (&gt;10.8mg/dl) documented by imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Crohn's related hospitalizations</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid prescriptions</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crohn's related surgeries</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in modified Harvey-Bradshaw Index (HBI without examination)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive protein</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fecal calprotectin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent with escalation of therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Patients who had to have a change in therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measure changes</measure>
    <time_frame>1 year</time_frame>
    <description>change in quality of life measures based on Inflammatory bowel disease questionnaire (IBD-Q) and CD-PRO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue measurements</measure>
    <time_frame>1 year</time_frame>
    <description>Change in FACIT-F scale over the year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crohn's related Emergency Department (ED) visits</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Low Dose Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be given 400 IU cholecalciferol once daily for 30 days. To maintain the blind, a random few will be given another round at the 30 day mark. For patients who enroll in the summer, a random few will again receive 400 IU cholecalciferol in March.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given cholecalciferol 10,000 IU daily for 30 days. At that point, if their vitamin D levels remain below 50 ng/ml, the 30 day course will be repeated. For patients who enroll in the summer, levels will be rechecked in March and if &lt;50 ng/ml, a 30 day course will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol 10,000 IU</intervention_name>
    <arm_group_label>High Dose Vitamin D</arm_group_label>
    <other_name>High Dose Vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol 400 IU</intervention_name>
    <arm_group_label>Low Dose Vitamin D</arm_group_label>
    <other_name>Low dose vitamin D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CD

          -  Age &gt;= 18 and &lt;75

          -  Vitamin D deficiency or insufficiency (serum 25-hydroxyvitamin D &lt; 30ng/ml)

        Exclusion Criteria:

          -  Corticosteroid use in the last 4 weeks

          -  CD-related surgery in the last 6 months

          -  CD-related hospitalization in the last 4 weeks

          -  Pregnancy, intended pregnancy during the study period or nursing

          -  Serum calcium &gt;10.2 mg/dL

          -  History of primary sclerosing cholangitis

          -  History of undergoing an ileal pouch-anal anastomosis

          -  Current active perianal disease

          -  History of nephrolithiasis in the past 2 years

          -  Anticipated change in therapy in the next 30 days (steroids, biologic initiation)

          -  modified Harvey-Bradshaw Index of 10 or more

          -  History of decreased renal function (glomerular filtration rate &lt;30ml/min based on
             MDRD) or polycystic kidney disease

          -  History of sarcoidosis

          -  History of hyperparathyroidism

          -  Any other chronic condition that may preclude high doses of Vitamin D such as
             lymphoma

          -  Concurrent use of hydrochlorothiazide, phenytoin, phenobarbital, carbamazepine or
             primidone

          -  Osteoporosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter D. Higgins, MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shail M Govani, M.D., M.Sc.</last_name>
    <role>Study Director</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Herfarth, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jørgensen SP, Agnholt J, Glerup H, Lyhne S, Villadsen GE, Hvas CL, Bartels LE, Kelsen J, Christensen LA, Dahlerup JF. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010 Aug;32(3):377-83. doi: 10.1111/j.1365-2036.2010.04355.x. Epub 2010 May 11.</citation>
    <PMID>20491740</PMID>
  </reference>
  <reference>
    <citation>Khalili H, Huang ES, Ananthakrishnan AN, Higuchi L, Richter JM, Fuchs CS, Chan AT. Geographical variation and incidence of inflammatory bowel disease among US women. Gut. 2012 Dec;61(12):1686-92. doi: 10.1136/gutjnl-2011-301574. Epub 2012 Jan 11.</citation>
    <PMID>22241842</PMID>
  </reference>
  <reference>
    <citation>Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000 Nov;130(11):2648-52.</citation>
    <PMID>11053501</PMID>
  </reference>
  <reference>
    <citation>Ananthakrishnan AN, Khalili H, Higuchi LM, Bao Y, Korzenik JR, Giovannucci EL, Richter JM, Fuchs CS, Chan AT. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology. 2012 Mar;142(3):482-9. doi: 10.1053/j.gastro.2011.11.040. Epub 2011 Dec 9.</citation>
    <PMID>22155183</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 21, 2016</lastchanged_date>
  <firstreceived_date>August 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Peter Higgins</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Crohn's disease</keyword>
  <keyword>Vitamin D deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
